LAB INTERNATIONAL BEGINS LAB CGRP TRIAL

A A

LAB International has enrolled the first patient in its LAB CGRP Phase IIa trial. The trial is expected to be completed in the third quarter of 2006.

The objectives of this randomized, double blind, cross-over Phase II study are to investigate the protective efficacy of LAB CGRP on metacholine induced bronchial hyper-responsiveness in adult patients with mild-to-moderate asthma, to compare this efficacy to salbutamol and placebo and to evaluate the safety and tolerability of LAB CGRP in asthma patients. The trial is enrolling a total of 12 patients.